Evidence map›Paper›PMID 29679299›Full record

ArticleMolecular imaging and biology2018

Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Paul Flechsig, Ramin Rastgoo, Clemens Kratochwil, Ole Martin, Tim Holland-Letz, Alexander Harms, Hans-Ulrich Kauczor, Uwe Haberkorn, Frederik L Giesel

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. European journal of nuclear medicine and molecular imaging · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paul FlechsigDepartment of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany. paul.flechsig@med.uni-heidelberg.de.
Ramin RastgooDepartment of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Clemens KratochwilDepartment of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Ole MartinMedical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, 40225, Dusseldorf, Germany.
Tim Holland-LetzDepartment of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Alexander HarmsInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Hans-Ulrich KauczorTranslational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Uwe HaberkornDepartment of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
Frederik L GieselDepartment of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTumor delineation within an atelectasis in lung cancer patients is not always accurate. When T staging is done by integrated 2-deoxy-2-[ PROCEDURES: Seventy-two patients with histologically proven lung cancer and adjacent atelectasis were investigated. Non-contrast-enhanced [

resultsCT density of the primary (36.4 Hounsfield units (HU) ± 6.2) was significantly higher compared to that of atelectatic lung (24.3 HU ± 8.3; p < 0.01), irrespective of the histological subtype. The discrimination between different malignant tumors using density analysis failed. SUVmax was increased in squamous cell carcinomas compared to adenocarcinomas. Irrespective of the malignant subtype, a possible cutoff value of 24 HU may help to exclude the presence of a primary in lesions below 24 HU, whereas a density above a threshold of 40 HU can help to exclude atelectatic lung.

conclusionDensity measurements in patients with lung cancer and surrounding atelectasis may help to delineate the primary tumor, irrespective of the specific lung cancer subtype. This could improve T staging and radiation treatment planning (RTP) without additional application of a contrast agent in CT, or an additional magnetic resonance imaging (MRI), even in cases of lung tumors of neuroendocrine differentiation or in slowly growing tumors with less avidity to [

Indexed as

Positron Emission Tomography Computed TomographyTomography, X-Ray ComputedAgedArea Under CurveFemaleFluorodeoxyglucose F18HumansLung NeoplasmsMaleNeoplasm StagingPulmonary AtelectasisROC CurveFluorodeoxyglucose F18Computed tomographyFDG-PET/CTLung cancerStaging

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.